Pfizer Injectables announces the addition of methotrexate injection, USP, to its growing portfolio of generic oncology products. Methotrexate is indicated for certain types of neoplastic diseases, a severe recalcitrant disabling type of psoriasis that is not adequately responsive to other forms of therapy, and certain types of active rheumatoid arthritis (RA) in adults and children. For a complete listing of indications and safety information including boxed warning, see the full prescribing information available at pfizerinjectables.com.